Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

EXCLUSIVE: Championed by the Daily Express, it has hailed 'amazing progress' for the 11,300 living with the genetic condition ...

JEFF KOWALSKY / AFP / Getty Images The 2024 presidential election ... are among the technology firms reporting this week, ...

Scientists reprogrammed a woman's fat cells to become insulin-making beta cells, reversing her type 1 diabetes.

Since Blueprint Medicines’ inception over a decade ago, we have focused on advancing the understanding of the underlying ...